Abiomed’s cardiopulmonary bypass system was cleared by the U.S. Food and Drug Administration (FDA) today (10/27) proceeding their April acquisition of Breethe. The effects of COVID-19 have created an increased need for heart recovery in cardiogenic shock patients. Abiomed presented data from Impella, a similar and complementary medical device for respiratory failure patients, at the Cardiovascular Research Foundation’s scientific symposium.

Learn more here

More on: